ThaiPR.NET https://www.thaipr.net/location/newton-mass-and-florence-italy Press Release Distribution Center of Thailand Wed, 29 Apr 2026 15:59:23 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy]]> https://www.thaipr.net/en/health_en/3305697 Thu, 23 Feb 2023 08:04:01 +0700 health_en https://www.thaipr.net/en/health_en/3305697 – Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the United Kingdom’s (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has granted […]

The post Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy appeared first on ThaiPR.NET.

]]> <![CDATA[Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis]]> https://www.thaipr.net/en/health_en/3260745 Thu, 03 Nov 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3260745 Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the U. […]

The post Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis appeared first on ThaiPR.NET.

]]> <![CDATA[Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy]]> https://www.thaipr.net/en/health_en/3216055 Fri, 22 Jul 2022 12:28:28 +0700 health_en https://www.thaipr.net/en/health_en/3216055 – Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical […]

The post Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy appeared first on ThaiPR.NET.

]]> <![CDATA[Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma]]> https://www.thaipr.net/en/health_en/3192977 Mon, 23 May 2022 14:25:15 +0700 health_en https://www.thaipr.net/en/health_en/3192977 — European Commission Decision Anticipated within Approximately 60 Days — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion […]

The post Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma appeared first on ThaiPR.NET.

]]> <![CDATA[Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories]]> https://www.thaipr.net/en/health_en/3137547 Thu, 23 Dec 2021 08:00:03 +0700 health_en https://www.thaipr.net/en/health_en/3137547 – Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries – Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202.5 Million in Future Milestones, Plus Tiered, Double-digit Royalties on Net […]

The post Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories appeared first on ThaiPR.NET.

]]>